Core Viewpoint - The stock of Hema Technology Co., Ltd. (禾迈股份) experienced a 5.36% increase on February 3, with a trading volume of 224 million yuan and a market capitalization of 13.257 billion yuan [1] Group 1: Company Overview - Hema Technology specializes in the research, development, manufacturing, and sales of photovoltaic inverters, energy storage products, and electrical equipment [2][7] - The company's main products include micro-inverters, monitoring devices, distributed photovoltaic power generation systems, modular inverters, and energy storage systems [2][7] - Hema Technology has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [2] Group 2: Financial Performance - For the period from January to September 2025, Hema Technology reported a revenue of 1.323 billion yuan, representing a year-on-year growth of 4.57% [8] - The company recorded a net profit attributable to shareholders of -59.115 million yuan, a significant decrease of 124.07% year-on-year [8] - As of September 30, the number of shareholders increased to 10,200, with an average of 12,134 circulating shares per person, a decrease of 3.68% [8] Group 3: Market Dynamics - The company benefits from a 64.25% share of overseas revenue, aided by the depreciation of the RMB [3] - Hema Technology is set to receive an investment of no less than 111.5 million yuan and up to 223 million yuan from Hangkai Holdings Group, supported by a special loan from China CITIC Bank [3] Group 4: Technical Analysis - The average trading cost of Hema Technology's shares is 109.02 yuan, with recent trends indicating a rapid exit of shares [6] - The current stock price is near a support level of 106.60 yuan, which is critical for potential rebound or further decline [6]

北交所新股申购报告 海圣医疗（920166.BJ）：麻醉监护医疗器械小巨人，麻醉监护精准化矩阵驱动成长 北交所研究团队 ——北交所新股申购报告 | 诸海滨（分析师） | 车欣航（分析师） | | --- | --- | | zhuhaibin@kysec.cn | chexinhang@kysec.cn | | 证书编号：S0790522080007 | 证书编号：S0790525050001 | 海圣医疗：麻醉、监护类医疗器械细分领域国家级专精特新"小巨人" 海圣医疗是面向全球的麻醉、监护类医疗器械综合产品提供商，为国内该细分领 域头部企业，获评国家级专精特新"小巨人"、浙江省隐形冠军企业等。公司产 品广泛应用于麻醉科、ICU、急诊科等临床科室。技术研发上，截至 2025 年 6 月 30 日，公司已先后承担国家、省、市级重大科技项目十余项，已累计获国家 授权专利 63 项，其中发明专利 13 项。经营层面，2024 年公司营收 3.04 亿元， 同比微降 0.70%，归母净利润 7091.75 万元；2025 年前三季度营收、归母净利润 同比分别增长 19.89%、26.70%，增长态势向好。2024 年 ...

来源：新浪证券-红岸工作室 2月2日，海泰新光跌1.01%，成交额1.17亿元，换手率2.04%，总市值56.22亿元。 异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 资金分析 今日主力净流入-772.68万，占比0.07%，行业排名100/135，连续2日被主力资金减仓；所属行业主力净 流入-6.62亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-772.68万-837.92万-850.46万-1696.85万-747.98 ...

Investment Rating - The investment rating for the company is "Hold" (initial coverage) [1] Core Viewpoints - The company, Zhigao Machinery, is a specialized manufacturer in the rock drilling equipment sector and has been recognized as one of the top 50 mining equipment manufacturers in China. The company focuses on providing energy-efficient, environmentally friendly, and high-efficiency drilling and air compressor products, with a strong emphasis on overseas market expansion [5][9][16] - The company's revenue for 2023 and 2024 is projected to be 840.37 million and 888.44 million yuan, respectively, reflecting year-on-year growth rates of 5.70% and 5.72%. This growth is supported by the "Belt and Road" initiative and an increase in the contribution of high-value-added integrated drilling machines [9][28] - The company has achieved a significant increase in overseas revenue, which grew from 0.13 million yuan in 2020 to 2.27 million yuan in 2024, with a compound annual growth rate of 104.23% [9][42] Financial Forecast - Total revenue is forecasted to reach 921.83 million yuan in 2025, with a growth rate of 3.76%, and 1,006.02 million yuan in 2026, with a growth rate of 9.13% [7] - The net profit attributable to shareholders is expected to be 124.83 million yuan in 2025, with a growth rate of 18.84%, and 151.37 million yuan in 2026, with a growth rate of 21.26% [7] - The company's earnings per share (EPS) is projected to be 1.40 yuan in 2025 and 1.70 yuan in 2026 [7] Company Overview - Zhigao Machinery was established in 2003 and is recognized as a high-tech enterprise specializing in the research, production, and sales of rock drilling equipment and air compressors. The company has a diverse product matrix and is actively involved in global market expansion [9][16][25] - The company has a stable and concentrated shareholding structure, with the largest shareholder holding 33.18% of the shares, which supports long-term development [19] Market Demand and Trends - The demand for rock drilling equipment is expected to grow due to increased infrastructure investment and mining activities, particularly in developing countries [47][61] - The company is focusing on high-end, automated, and intelligent drilling products, which are seen as the core direction for upgrading rock drilling equipment [60][67] - The global market for rock drilling equipment is projected to reach 831 million USD by 2031, with a compound annual growth rate of 4.60% from 2025 to 2031 [47][50]

Core Viewpoint - The company, Zhejiang Huilong New Materials Co., Ltd., is actively expanding its business through strategic investments in the pet industry and enhancing its international trade operations, particularly in countries along the Belt and Road Initiative. Group 1: Company Developments - The company has recently invested 6 million yuan for a 2.2% stake in Hangzhou Pet Sales Supply Chain Management Co., aiming to leverage digital infrastructure in the pet industry, which is experiencing rapid growth in China [3] - Huilong New Materials focuses on the research and production of environmentally friendly fibers, which can be applied in pet products, and has received multiple certifications for its green products [3] - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [4] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 674 million yuan, representing a year-on-year growth of 11.26%, and a net profit attributable to shareholders of 30.74 million yuan, up 25.88% year-on-year [9] - The company has distributed a total of 103 million yuan in dividends since its A-share listing, with 81.52 million yuan distributed over the past three years [9] Group 3: Market Position and Strategy - The company's main export markets include Indonesia, Pakistan, Thailand, and Turkey, which are primarily emerging markets along the Belt and Road [2] - Huilong New Materials is enhancing its marketing efforts by collaborating with international trade platforms and trade shows to attract potential domestic and international clients [4] - The company’s stock has shown a recent decline of 1.66%, with a total market capitalization of 4.364 billion yuan [1]

Core Viewpoint - Wuzhou Medical's stock experienced a slight decline of 0.37% on February 2, with a total market capitalization of 2.71 billion yuan and a trading volume of 37.90 million yuan [1] Business Overview - The company specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion sets, and other related medical supplies [2] - Wuzhou Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [2] Financial Performance - As of the 2024 annual report, overseas revenue accounted for 96.88% of total revenue, benefiting from the depreciation of the Renminbi [3] - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Shareholder and Market Activity - As of January 20, the number of shareholders decreased by 2.28% to 5,364, with an average of 7,488 circulating shares per person, which increased by 2.33% [7] - The company has distributed a total of 81.60 million yuan in dividends since its A-share listing [8] - Notably, as of September 30, 2025, the fund "Noan Multi-Strategy Mixed A" exited the list of the top ten circulating shareholders [9]

Core Viewpoint - Aidi Te (Qinhuangdao) Technology Co., Ltd. is experiencing growth in its dental medical and medical device sectors, benefiting from the depreciation of the RMB and its status as a "specialized, refined, and innovative" enterprise [2][3]. Company Overview - Aidi Te specializes in the research, production, and sales of dental restoration materials and digital dental equipment, with main products including dental restoration materials, digital dental devices, orthodontic products, and preventive dental products [2]. - The company was established on March 15, 2007, and is located in Qinhuangdao, Hebei Province. It was listed on June 26, 2024 [8]. - The revenue composition of Aidi Te includes 73.74% from dental restoration materials, 19.80% from digital dental equipment, and 6.46% from other products and services [8]. Financial Performance - For the period from January to September 2025, Aidi Te achieved a revenue of 747 million yuan, representing a year-on-year growth of 16.44%, and a net profit attributable to shareholders of 142 million yuan, with a growth of 27.40% [8]. - The company has a total market capitalization of 5.456 billion yuan, with a trading volume of 120 million yuan and a turnover rate of 3.23% on February 2 [1]. Market Position and Recognition - Aidi Te has been recognized as a national-level "specialized, refined, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [2]. - The company benefits from a significant overseas revenue share of 61.85%, which is positively impacted by the depreciation of the RMB [3]. Product Innovation - The company produces the CPD-100 3D printer, capable of achieving high-precision printing at 30 nanometers [4].

Core Viewpoint - The company, Yingjixin Technology Co., Ltd., has experienced a decline in stock price and trading volume, while continuing to develop and produce automotive and consumer electronics chips, indicating both growth potential and current market challenges [1][4]. Group 1: Company Overview - Yingjixin specializes in the research and sales of power management and fast charging protocol chips, with its main products including power management chips (65.15% of revenue), mixed-signal SoC (22.02%), and battery management chips (12.33%) [7]. - The company has successfully developed automotive-grade charging chips that meet AEC-Q100 standards and has begun mass production for domestic and international automotive manufacturers [2]. - Yingjixin has been recognized as a "specialized and innovative" small giant enterprise, which signifies its strong market position and technological capabilities [3]. Group 2: Financial Performance - For the period from January to September 2025, Yingjixin reported a revenue of 1.169 billion yuan, representing a year-on-year growth of 14.16%, and a net profit attributable to shareholders of 114 million yuan, up 28.54% year-on-year [8]. - The company has distributed a total of 171 million yuan in dividends since its A-share listing, with 155 million yuan distributed over the past three years [8]. Group 3: Market Activity - On February 2, the stock price of Yingjixin fell by 3.97%, with a trading volume of 290 million yuan and a turnover rate of 2.68%, leading to a total market capitalization of 10.584 billion yuan [1]. - The stock has seen a net outflow of 12.658 million yuan from major investors, indicating a trend of reduced holdings over the past three days [5].

Core Viewpoint - Jianghan New Materials has released 122 million restricted shares for circulation, with several executives committing not to reduce their holdings within a year, indicating confidence in the company's future development and aiming to alleviate short-term market pressure from the share unlock [1][3]. Group 1: Share Unlocking Details - Jianghan New Materials announced that 122 million shares, accounting for 32.58% of the total share capital, will be released for circulation starting February 2, 2026, due to the end of a 36-month lock-up period [1][3]. - The company’s eight directors and senior management have pledged not to transfer or reduce their holdings from February 2, 2026, to February 1, 2027, which is intended to convey management's confidence in the company's future [3]. Group 2: Company Background and Operations - Jianghan New Materials specializes in the research, production, sales, and import-export trade of functional organosilicon and other silicon-based new materials, recognized as a national manufacturing champion and a "little giant" enterprise [3]. - The company is accelerating capacity expansion with a new 60,000 tons/year trichlorosilane project planned in its green circular industry park, which will increase its total trichlorosilane capacity to 120,000 tons/year [3][4]. Group 3: Production and Global Expansion - The new facility addresses the mismatch between trichlorosilane production capacity and the current and future growth of silane production, utilizing HCL, a byproduct of silane production, as a raw material for trichlorosilane [4]. - Jianghan New Materials is deepening its global layout with over ten overseas warehouses established in Southeast Asia, Europe, and the United States, and plans to initiate overseas manufacturing to solve local service challenges [4].

Core Viewpoint - The event "For China's Economy, Cheers to Entrepreneurs" highlighted the emergence of a new generation of entrepreneurs in China, focusing on advanced technologies such as brain-machine interfaces, autonomous driving, and low-altitude economy, showcasing their impact on society and the economy [1][3][29]. Group 1: Technological Innovations - Strong Brain Technology's smart bionic hand has assisted over 10,000 individuals with upper or lower limb disabilities, allowing them to live and work normally [29]. - The L4 autonomous vehicle from Pony.ai operates without a driver, demonstrating advancements in autonomous driving technology [29]. - The flying car developed by Huitian has received 7,000 global orders and plans to start deliveries by the end of 2026, with a next-generation model capable of carrying six people for 500 kilometers [29]. Group 2: New Quality Entrepreneurs - The 2025 "Top Ten Economic Figures" includes four entrepreneurs associated with cutting-edge technologies: Liu Debing from Zhipu, Peng Jun from Pony.ai, Han Bicheng from Strong Brain Technology, and Zhao Deli from Huitian [31]. - The evaluation committee also recognized groups involved in "China's Chip Infrastructure," highlighting the shift towards new quality productivity driven by technological breakthroughs and innovative resource allocation [31][32]. Group 3: Economic Strategy and Consumer Focus - The "14th Five-Year Plan" emphasizes enhancing the competitiveness of traditional industries while promoting new demand to drive supply [32]. - Three representatives from the consumer and lifestyle sector were recognized: Leng Youbin from China Feihe, Ma Yin from Anaya, and Wu Xiangdong from Zhenjiu Lidu Group [32]. Group 4: Historical Context of Entrepreneurs - The evolution of Chinese entrepreneurs has gone through 15 stages since the reform and opening up, from the emergence of individual private economies to the current focus on high-quality development and innovation [35][36][37]. - The current entrepreneurial landscape is characterized by a significant shift towards new quality productivity, with a focus on advanced manufacturing and technology-driven solutions [51]. Group 5: Future Outlook - The future of China's economy is expected to continue along the path of high-quality development, leveraging new technologies and innovative business models [52]. - The "single person + AI as a company" model represents a new entrepreneurial path empowered by technology, indicating a shift in how businesses operate and innovate [52].